Nareg Varjabedian: Biosimilars – A Landscape of Innovation and Regulatory Nuances
Nareg Varjabedian, Regulatory Affairs Team Lead at ClinChoice, shared a post on LinkedIn:
“Biosimilars: A Landscape of Innovation and Regulatory Nuances.
Biosimilars are a rapidly growing class of medications offering a promising future for healthcare accessibility and affordability.
But navigating the world of biosimilars requires understanding not only their therapeutic value but also the subtle differences in regulatory frameworks across jurisdictions.
This article prepared by my colleague Anahit Grigoryan and myself, delves into the world of biosimilars, exploring their definition, indications, cost benefits, and the exciting possibilities for future advancements.
Join the Conversation!
Share your thoughts on the future of biosimilars and the role of research in driving innovation. Let’s work together to ensure biosimilars reach their full potential in improving patient lives worldwide.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023